A virally safe, thrombin-free factor-Xla concentrate or a coagulation factor concentrate which contains factor Xla as an active pharmaceutical ingredient and which is obtained by fractionation of plasma or serum or by genetic engineering and is suitable for the treatment of coagulation disorders attributable to diminished and/or delayed thrombin formation.